Alanna Sedgwick
About Alanna Sedgwick
Alanna Sedgwick is a scientist known for developing a novel assay to visualize cholesterol efflux from cells, contributing to research in various diseases. She currently works as a Postdoctoral Research Associate at the University of Notre Dame, where she studies the E3 ubiquitin ligase tumor suppressor von Hippel-Lindau.
Work at Capricor Therapeutics
There is no information available regarding any association with Capricor Therapeutics.
Current Position at University of Notre Dame
Alanna Sedgwick has been working as a Postdoctoral Research Associate at the University of Notre Dame since 2014. In this role, she focuses on studying the E3 ubiquitin ligase tumor suppressor von Hippel-Lindau (VHL) and its impact on cell migration, adhesion, proliferation, and invasion. She is also involved in screening drug candidates aimed at reducing tumor cell aggressiveness associated with VHL loss.
Previous Experience at United Cerebral Palsy
From 2004 to 2007, Alanna Sedgwick served as the Equine Coordinator at the Saddle Pals Therapeutic Center, part of United Cerebral Palsy, in Washington, D.C. During her three-year tenure, she coordinated therapeutic equine activities, contributing to the center's mission of providing support to individuals with disabilities.
Education and Expertise
Alanna Sedgwick earned her Bachelor of Arts in Biology from California State University - Sacramento from 2004 to 2007. She then attended the University of Notre Dame, where she studied Molecular Biology and Philosophy, achieving her Doctor of Philosophy from 2007 to 2013. Her academic background equips her with a strong foundation in biological sciences and research methodologies.
Research Contributions
Throughout her career, Alanna Sedgwick has made significant contributions to the field of cellular biology. She developed a novel assay to visualize cholesterol efflux from cells, which is instrumental in assessing drug activity and the effects of cell signaling modulation. Additionally, she identified proteins and post-translational modifications that mediate cellular cholesterol efflux, impacting research in various areas, including cholesterol storage disorders, neurodegenerative diseases, cancer metabolism, and cardiovascular diseases.